Form 4: InspireMD Director Raymond Cohen Receives Stock Grant

InspireMD, Inc. director Raymond W. Cohen was granted 44,030 shares of restricted common stock, vesting in January 2027.

Summary

• Raymond W. Cohen, a Director of InspireMD, Inc. (NSPR), acquired 44,030 shares of common stock.
• These shares are restricted stock and were granted at a price of $0.
• The shares are scheduled to vest on January 14, 2027, contingent upon Mr. Cohen's continued service to the company.
• Following this transaction, Mr. Cohen directly beneficially owns a total of 92,417 shares of common stock.
• Mr. Cohen has granted Michael Lawless, an individual at InspireMD, Inc., a Power of Attorney to prepare and file SEC Forms 3, 4, and 5 on his behalf, executed on January 16, 2026.

Sentiment

Score: 7

Explanation: The filing reflects a routine, positive action of granting equity compensation to a director, aligning interests and indicating continued commitment, with no negative implications.

Positives

• The grant of restricted stock aligns the director's interests with long-term shareholder value, as vesting is contingent on continued service.
• The transaction indicates ongoing commitment and involvement of a key director in the company's future.

Risks

• The vesting of the restricted stock is subject to the reporting person's continued service, meaning the shares could be forfeited if service ceases before January 14, 2027.

Future Outlook

The vesting schedule for the restricted stock on January 14, 2027, indicates a forward-looking incentive for the director's continued service and alignment with future company performance.

Industry Context

This is a standard equity compensation practice for directors in publicly traded companies, aiming to align their interests with long-term shareholder value. It does not provide specific industry-wide insights.

Comparison to Industry Standards

• Granting restricted stock to directors is a common practice across various industries for executive and director compensation, aligning their incentives with long-term company performance.
• The specific number of shares and vesting schedule would typically be benchmarked against peer companies in the biotechnology or medical device sector (InspireMD's likely industry) to ensure competitive and appropriate compensation.

Corporate Governance

Related Party Transactions

• Grant of 44,030 restricted common stock shares to Raymond W. Cohen, a Director of InspireMD, Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with long-term shareholder value, as vesting is tied to continued service and potential stock appreciation.
• Management: The Power of Attorney streamlines administrative tasks for the director and the company's compliance team.

Next Steps

• The restricted stock shares are scheduled to vest on January 14, 2027, subject to Raymond W. Cohen's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine restricted stock grant to a director, which is a standard compensation practice designed to align management interests with long-term shareholder value. It does not present new information that would fundamentally alter the investment thesis for InspireMD, Inc. Therefore, a "hold" recommendation is appropriate, as the filing itself does not provide a strong catalyst for either buying or selling the stock, but rather confirms ongoing corporate governance and compensation practices.

Keywords

InspireMD, NSPR, Raymond W. Cohen, Restricted Stock, Stock Grant, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Compensation